The Effect of Quercetin in Sarcoidosis

The Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in Sarcoidosis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00402623

Enrollment

Registered

2006-11-22

Start date

2006-01-31

Completion date

2006-01-31

Last updated

2017-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoidosis

Keywords

sarcoidosis, quercetin, supplementation, oxidative stress, inflammation

Brief summary

The exact cause of the chronic lung disease sarcoidosis is still unknown. Consequently, a complete efficacious treatment is still not available. Earlier studies indicate an important key role for oxidative stress, i.e. an imbalance between the production of and the protection against ROS, in the etiology of sarcoidosis. Antioxidants, needed for protection against ROS, are indeed lower in sarcoidosis. Therefore, antioxidant therapy to strengthen the reduced antioxidant defense might be efficacious in sarcoidosis treatment. Since ROS are also capable of initiating and mediating inflammation, antioxidant therapy might also mitigate the elevated inflammation that occurs in sarcoidosis. The flavonoid quercetin possesses both anti-oxidative and anti-inflammatory capacities and might therefore serve as a good candidate for antioxidant therapy in sarcoidosis. Therefore, the aim of the present study is to determine the effect of quercetin supplementation in sarcoidosis patients on markers of both oxidative stress and inflammation.

Interventions

DIETARY_SUPPLEMENTquercetin

1000 mg quercetin within 24 hours

OTHERplacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* clinical diagnosis of sarcoidosis with emphasize on pulmonary sarcoidosis * no smoking * no treatment

Exclusion criteria

* clinical diagnosis (and treatment) of other diseases * symptoms of sarcoidosis in other organs besides the lung * use of food supplements or vitamins

Design outcomes

Primary

Measure	Time frame
antioxidant status after 24 hours	24 hours
inflammatory status after 24 hours	24 hours

Secondary

Measure	Time frame
plasma quercetin concentration after 24 hours	24 hours
plasma malondialdehyde (MDA) levels after 24 hours	24 hours

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026